Company Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.
In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain.
It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company.
The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Country | United States |
| Founded | 1995 |
| IPO Date | Apr 7, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Michael Exton |
Contact Details
Address: 2445 Technology Forest Boulevard, 11th Floor The Woodlands, Texas 77381 United States | |
| Phone | 281 863 3000 |
| Website | lexpharma.com |
Stock Details
| Ticker Symbol | LXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001062822 |
| CUSIP Number | 528872302 |
| ISIN Number | US5288723027 |
| Employer ID | 76-0474169 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael S. Exton Ph.D. | Chief Executive Officer and Director |
| Scott M. Coiante | Senior Vice President and Chief Financial Officer |
| Brian T. Crum | Senior Vice President, General Counsel and Secretary |
| Wendy E. McDermott | Senior Vice President of Human Resources |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| Kristen L. Alexander | Vice President of Finance and Accounting |
| Lisa M. DeFrancesco | Senior Vice President of Investor Relations and Corporate Communications |
| Dr. Suma Gopinathan M.S., Ph.D. | Senior Vice President of Discovery |
| Rachel Yap Martens | Senior Vice President of Partnerships and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 16, 2026 | ARS | Filing |
| Mar 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 17, 2026 | D | Notice of Exempt Offering of Securities |
| Feb 6, 2026 | FWP | Free Writing Prospectus |
| Feb 2, 2026 | SCHEDULE 13D/A | Filing |
| Feb 2, 2026 | 8-K | Current Report |